Get the Stockscreener App
8.73
1.39%
0.12
Biocryst Pharmaceuticals Inc Stock (BCRX) Latest News
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Up 9.1%Still a Buy? - MarketBeat
BioCryst Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Hits New 1-Year HighWhat's Next? - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Short Interest Update - MarketBeat
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Inside BioCryst's Latest Executive Compensation Move: Key Details on New Hire Stock Grants - StockTitan
BioCryst Pharmaceuticals (NASDAQ:BCRX) Given "Market Outperform" Rating at JMP Securities - MarketBeat
CPRX: 3 Niche Healthcare Stocks Tackling Rare Diseases - StockNews.com
JMP Securities raises Pharvaris stock target to $55 - MSN
BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) large institutional owners must be happy as stock continues to impress, up 3.4% over the past week - Simply Wall St
JMP Securities maintains BioCryst stock with $18 target - MSN
Bullish BioCryst Pharmaceuticals Insiders Loaded Up On US$1.05m Of Stock - Yahoo Finance
Trading (BCRX) With Integrated Risk Controls - Stock Traders Daily
Fibrodysplasia Ossificans Progressiva Market Set to Grow Substantially Through 2032, DelveInsight Projects | Ipsen, Regeneron Pharmaceutical, Biocryst - Barchart
Fibrodysplasia Ossificans Progressiva Market Set to Grow - openPR
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 5.6%Still a Buy? - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Sold by Inspire Investing LLC - MarketBeat
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Immatics (NASDAQ:IMTX) - Defense World
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Receives $15.17 Average PT from Brokerages - MarketBeat
HRMY: 3 Under-the-Radar Biotech Stocks Revolutionizing Healthcare - StockNews.com
Trend Tracker for (BCRX) - Stock Traders Daily
JPMorgan Chase & Co. Decreases Holdings in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Drop in Short Interest - MarketBeat
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decline in Short Interest - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Down 3.4%Time to Sell? - MarketBeat
BioCryst releases preliminary 2024 results, 2025 guidance - MSN
Be Bio secures $92m for haemophilia B and hypophosphatasia treatments - Pharmaceutical Technology
Evercore ISI Forecasts Strong Price Appreciation for BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Stock Price Expected to Rise, Needham & Company LLC Analyst Says - Defense World
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.4%Time to Sell? - MarketBeat
BioCryst price target raised to $12 from $10 at Evercore ISI - Yahoo Finance
BioCryst's SWOT analysis: stock outlook amid orladeyo's growth and pipeline shifts - Investing.com
BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Raised to $12.00 - MarketBeat
BioCryst to Present at J.P. Morgan Conference - TipRanks
BioCryst Pharmaceuticals Releases Positive Financial Results and Guidance for 2025 - Defense World
BioCryst Pharmaceuticals Increases Wholesale Acquisition Cost for ORLADEYO®BioCryst Pharmaceuticals, Inc. has announced an increase in the wholesale acquisition cost (WAC) for ORLADEYO®, a medication used to treat various conditions in the United - Defense World
BioCryst stock target raised to $12 at Evercore ISI By Investing.com - Investing.com Canada
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 By Investing.com - Investing.com Australia
Exploring High Growth Tech Stocks In January 2025 - Simply Wall St
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap UpShould You Buy? - MarketBeat
BioCryst projects $515-$535 million in ORLADEYO sales for 2025 - Investing.com India
BioCryst Projects Strong Revenue Growth in 2024-2025 - TipRanks
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y) - The Manila Times
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® - GlobeNewswire
BioCryst adjusts price of ORLADEYO in the U.S. By Investing.com - Investing.com Australia
Objective long/short (BCRX) Report - Stock Traders Daily
BioCryst adjusts price of ORLADEYO in the U.S. - Investing.com
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):